CaltechAUTHORS
Published August 17, 2010 | Version Accepted Version + Supplemental Material
Journal Article Open

SIK2 Is a Centrosome Kinase Required for Bipolar Mitotic Spindle Formation that Provides a Potential Target for Therapy in Ovarian Cancer

Creators

  • 1. ROR icon The University of Texas MD Anderson Cancer Center
  • 2. ROR icon Hutchison/MRC Research Centre
  • 3. ROR icon Rosie Hospital
  • 4. ROR icon University of Cambridge
  • 5. ROR icon Peter MacCallum Cancer Centre
  • 6. ROR icon Cancer Research UK Cambridge Center

Abstract

Regulators of mitosis have been successfully targeted to enhance response to taxane chemotherapy. Here, we show that the salt inducible kinase 2 (SIK2) localizes at the centrosome, plays a key role in the initiation of mitosis, and regulates the localization of the centrosome linker protein, C-Nap1, through S2392 phosphorylation. Interference with the known SIK2 inhibitor PKA induced SIK2-dependent centrosome splitting in interphase while SIK2 depletion blocked centrosome separation in mitosis, sensitizing ovarian cancers to paclitaxel in culture and in xenografts. Depletion of SIK2 also delayed G1/S transition and reduced AKT phosphorylation. Higher expression of SIK2 significantly correlated with poor survival in patients with high-grade serous ovarian cancers. We believe these data identify SIK2 as a plausible target for therapy in ovarian cancers.

Additional Information

© 2010 Elsevier. Under an Elsevier user license. Received 4 January 2010, Revised 2 May 2010, Accepted 2 July 2010, Available online 16 August 2010. We would like to thank Dr. E. Nigg and Dr. M. Bornens for giving valuable reagents. We also thank Dr. R. Laskey, Dr. B. Hassan, and Dr. G. Smith for helpful comments on the manuscript. We thank Dr. G. Tzolovsky for technical help. This work was funded by Cancer Research UK, the University of Cambridge, the Zarrow Foundation, the Ovarian Cancer Research Fund Program Project Development Grant, and the University of Texas M.D. Anderson Cancer Center Ovarian Cancer Specialized Program of Research Excellence (P50 CA083639) and the Addenbrooke's Charitable Trust. A.A.A. is a Cancer Research UK Clinician Scientist. The AOCS was supported by The Cancer Council Victoria, Queensland Cancer Fund, The Cancer Council New South Wales, The Cancer Council South Australia, The Cancer Foundation of Western Australia, the Cancer Council Tasmania, and the National Health and Medical Research Council of Australia (NHMRC). The authors would like to thank Dr. M. Deery and members of the Cambridge Centre for Proteomics, Department of Biochemistry, University of Cambridge, members of the time-lapse microscopy facility (supported by NCI core grant 5P30CA016672-29), and members of the siRNA screening facility at the University of Texas M.D. Anderson Cancer Center for technical assistance. Detailed additional methods are available as Supplemental Information.

Attached Files

Accepted Version - nihms229878.pdf

Supplemental Material - 1-s2.0-S1535610810002746-mmc1.pdf

Supplemental Material - 1-s2.0-S1535610810002746-mmc2.xls

Supplemental Material - 1-s2.0-S1535610810002746-mmc3.xls

Supplemental Material - 1-s2.0-S1535610810002746-mmc4.xls

Supplemental Material - 1-s2.0-S1535610810002746-mmc5.xls

Supplemental Material - 1-s2.0-S1535610810002746-mmc6.mp4

Supplemental Material - 1-s2.0-S1535610810002746-mmc7.mp4

Supplemental Material - 1-s2.0-S1535610810002746-mmc8.mp4

Files

1-s2.0-S1535610810002746-mmc1.pdf

Files (9.4 MB)

Name Size
md5:acdf4f42ddcdc5147806a9e2ceb563a9
918.1 kB Preview Download
md5:af7490b4e2ea0bba7e4ca964588a2c11
516.1 kB Download
md5:0f0dc829ea1334b604822c8e7bd23ee0
19.5 kB Download
md5:383033ede3da1e6494c3e2ca2099dd35
505.3 kB Download
md5:39b5689d6be42c555a251bd098ffa199
27.1 kB Download
md5:b6b4a983eda4bfca5d876d7fd62e1719
881.9 kB Preview Download
md5:c55686135585dc5003873ac194fb002d
410.5 kB Preview Download
md5:cd1cb43e35ba8602bf96e201c3e1734c
738.8 kB Preview Download
md5:746c28f3f8873d70e0ecc665cc62d2a2
5.4 MB Preview Download

Additional details

Identifiers

PMCID
PMC3954541
Eprint ID
105607
DOI
10.1016/j.ccr.2010.06.018
Resolver ID
CaltechAUTHORS:20200928-150625661

Related works

Describes
10.1016/j.ccr.2010.06.018 (DOI)

Funding

Cancer Research UK
University of Cambridge
Zarrow Foundation
Ovarian Cancer Research Fund
NIH
P50 CA083639
Addenbrooke's Charitable Trust
Cancer Council Victoria
Queensland Cancer Fund
Cancer Council New South Wales
Cancer Council South Australia
Cancer Foundation of Western Australia
Cancer Council Tasmania
National Health and Medical Research Council (NHMRC)
NIH
5P30CA016672-29

Dates

Created
2020-09-29
Created from EPrint's datestamp field
Updated
2021-11-16
Created from EPrint's last_modified field